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Background: During continuous venovenous haemofiltration (CVVH), regional anticoagulation with citrate may be
superior to heparin in terms of biocompatibility, since heparin as opposed to citrate may activate complement
(reflected by circulating C5a) and induce neutrophil degranulation in the filter and myeloperoxidase (MPO) release
from endothelium.
Methods: No anticoagulation (n = 13), unfractionated heparin (n = 8) and trisodium citrate (n = 17) regimens during
CVVH were compared. Blood samples were collected pre- and postfilter; C5a, elastase and MPO were determined
by ELISA. Additionally, C5a was also measured in the ultrafiltrate.
Results: In the heparin group, there was C5a production across the filter which most decreased over time as
compared to other groups (P = 0.007). There was also net production of elastase and MPO across the filter during
heparin anticoagulation (P = 0.049 or lower), while production was minimal and absent in the no anticoagulation
and citrate group, respectively. During heparin anticoagulation, plasma concentrations of MPO at the inlet increased
in the first 10 minutes of CVVH (P = 0.024).
Conclusion: Citrate confers less filter-induced, potentially harmful complement activation and neutrophil
degranulation and less endothelial activation than heparin when used for anticoagulation during continuous venovenous
haemofiltration in critically ill patients.
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Acute kidney injury (AKI) is common in critically ill
patients and carries a high mortality rate [1]. To tem-
porarily replace renal function, continuous venovenous
haemofiltration (CVVH) is often used. Anticoagulation
is required to prevent clotting of the extracorporeal sys-
tem. Frequently used modes of anticoagulation include* Correspondence: a.b.j.groeneveld@erasmusmc.nl
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reproduction in any medium, provided the orsystemic heparin and regional citrate administration.
Heparin is contraindicated in patients with a high
bleeding tendency or heparin-induced thrombocytopenia
and regional anticoagulation by citrate, in which only the
extracorporeal circuit is anticoagulated by chelation of
calcium, can then be used safely and effectively [2,3].
Potential benefits of the latter may include prolonged
filter survival times and improved biocompatibility of
the filter and this may help to explain the lower mortal-
ity rates of citrate-CVVH found by others [3,4].l Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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response to various components of CVVH [5-7], including
complement activation and C5a release followed by poly-
morphonuclear cell degranulation with release of intra-
cellular products such as elastase, complexed in the
circulation to alpha1-antitrypsin, and myeloperoxidase
(MPO). The type of anticoagulation could contribute to
the magnitude of the inflammatory response. As dem-
onstrated in intermittent haemodialysis and in blood
in vitro, calcium-chelating citrate anticoagulation may
lower polymorphonuclear cell degranulation as observed
with heparin; this may be partly independent of comple-
ment activation since cations, such as calcium, may be
pivotal in cell activation and degranulation [8-15]. Never-
theless, the use of citrate may also prevent activation of
complement by blood-membrane contact and endothelial
release of MPO, as seen during heparin anticoagulation
[16]. The single prior, albeit small, study suggesting pre-
vention of neutrophil degranulation with citrate-CVVH as
compared to heparin lacked a control group (no antic-
oagulation) and measurements of complement activation
products [15].
We therefore hypothesized that regional anticoagula-
tion with citrate causes less complement activation,
polymorphonuclear cell degranulation and endothelial
MPO release as compared to heparin, during CVVH in
critically ill patients with AKI. We studied these vari-
ables for the first filter applied in critically ill patients
with AKI in need of renal replacement therapy and
who were either not anticoagulated or anticoagulated
with citrate or heparin.
Methods
The patient population and methods for this study are
reported elsewhere [3,7]. In brief, the first study started
one year before the availability of a custom-made citrate-
based replacement fluid. From March 2004 to September
2005, patients admitted to the ICU who developed AKI
necessitating CVVH but did not receive heparin due to
a high bleeding tendency, either received anticoagulant-
free CVVH (n = 13) or, after becoming available in 2005,
regional citrate anticoagulation (n = 10) and were pro-
spectively followed. High risk for bleeding was arbitrarily
defined as a platelet count of less than 40 x109/L, an acti-
vated partial thromboplastin time (aPTT) of more than
60 seconds, a prothrombin time of more than 2.0 inter-
national normalized ratio, a recent major bleeding, or
active bleeding. Because all patients were treated accord-
ing to local standards, the need for informed consent was
waived for this study. Patients were also recruited from
a second study which is a randomized controlled trial
initiated in 2006 (the so called ‘Citrate anticoagulation
versus systemic heparinization’, CASH trial, clinicaltrials.
gov number NCT00209378, manuscript in preparation).Patients admitted to the ICU who developed AKI ne-
cessitating CVVH without a high bleeding risk, were
randomized between unfractionated heparin as anti-
coagulant (n = 8) or citrate (n = 7). Informed consent
was obtained from all study participants or their next-
of-kin. Study protocols were approved by the local medical
ethical committee and performed in accordance with
the Declaration of Helsinki.
Treatment protocol
The indication for CVVH was based on standard clinical
indications that include AKI accompanied by haemo-
dynamic instability, ongoing hypercatabolism, diuretic-
resistant fluid overload, respiratory distress, multiorgan
failure, or some combinations of these factors. CVVH was
performed using a haemofiltration machine (DIAPACT, B.
Braun Medical, Melsungen, Germany). Vascular access
was obtained by the insertion of an 11 F double-lumen
catheter (GAMCATH, Gambro, Hechingen, Germany)
into the femoral, subclavian, or internal jungular vein.
A 1.9 m2 highly permeable cellulose triacetate filter
(NIPRO UF-205, Nissho Corp, Osaka, Japan, cutoff
approximately 40 kDa) was used in all treatments. For
lactate- or bicarbonate-based CVVH, commercially pre-
pared buffer solutions were used (BH504 [lactate-based]
or HF32bic [bicarbonate-based] in n = 6 Group 1 and n =
5 in Group 2, Dirinco, Rosmalen, the Netherlands); the
lactate solution contained 140 mmol/L sodium, 1.5 mmol/
L potassium, 1.5 mmol/L calcium, 103 mmol/L chloride,
11.1 mmol/L glucose, and 42 mmol/L lactate; the bi-
carbonate solution contained 140 mmol/L sodium,
2.0 mmol/L potassium, 0.5 mmol/L magnesium, 1.75 mmol/
L calcium, 111.5 mmol/L chloride, 1.0 mmol/L glucose,
32.0 mmol/Lbicarbonate and 3.0 mmol/L lactate. Patients
with high serum lactate levels (>5 mmol/L) were routinely
treated with bicarbonate-buffered rather than lactate
buffered CVVH. For the use of citrate, a replacement
solution was custom-made by Dirinco (Rosmalen, the
Netherlands), according to the protocol described be-
fore [3]. The solution contained 139.9 mmol/L sodium,
3.0 mmol/L potassium, 0.5 mmol/L magnesium, no cal-
cium, 104 mmol/L chloride, 5 mmol/L glucose and
13.3 mmol/L citrate. Blood flow rate was set at
180 mL/min in all groups. Replacement fluid was ad-
ministered at a standard rate of 2000 mL/h in the pa-
tients receiving no anticoagulation or heparin with
bicarbonate or lactate-containing replacement fluids.
Patients on heparin were administered a heparin bolus
of 5000 IU followed by a body weight based continuous
infusion in order to reach an activated partial thrombo-
plastin time (aPTT) between 55–65 seconds. Replacement
fluid rates in the citrate group were set at 2400 mL/h.
Replacement fluids were infused in predilutional mode.
Patients receiving citrate-based therapy had a separate
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Sandoz, containing 0.225 mmol/mL calcium, Novartis
Consumer Health, Breda, The Netherlands). Calcium
administration was adapted to concentrations of ionized
calcium in the patient by a specially designed algorithm,
as described before [3]. The target ionized calcium con-
centration in the circuit was 0.3 mmol/L, but not routinely
monitored since this is almost uniformly achieved with
the indicated settings [3].
Study protocol
At inclusion, demographic variables were recorded such as
age, gender and reason of intensive care unit (ICU) admis-
sion. Assessment of disease severity on ICU admission was
done according to the simplified acute physiology score II
(SAPS II) and the sequential organ failure assessment score
(SOFA). We collected systemic inflammatory response
syndrome (SIRS) criteria: body temperature >38°C; a
heart rate of >90 beats/min; a respiratory rate of >20
breaths/min or mechanical ventilation; and white blood
cell counts of <4.0 *109/L or >12.0 *109/L. When SIRS (2 or
more criteria) and an infection were present (either clinic-
ally suspected or microbiologically confirmed), patients
were classified as having sepsis. Venous blood samples
were collected from the haemofiltration catheter from
each patient before the initiation of CVVH and adminis-
tration of heparin. Heparin was given immediately after
filter connection. Thereafter, blood samples were collected
after 10, 60, 180 and 720 min from the pre- and postfilter
pole. Prefilter blood was drawn before addition of re-
placement fluids. Leukocytes, platelets, aPTT and serum
creatinine concentrations were measured before initiation
of CVVH and after 720 minutes. In all patients, a zero
fluid balance was achieved during the time points at
which blood samples were drawn. Samples were col-
lected in standard Vacutainer tubes (Becton, Dickinson
and Company, Erembodegem, Belgium) with ethylene-
diaminetetraacetic acid (EDTA), benzamidine and soybean
trypsin inhibitor added. For C5a, ultrafiltrate samples
were collected from the appropriate ports. Samples
were centrifuged at 1,300 g for 10 minutes at 4°C and
stored at −80°C until assayed.
Measurements and calculations
C5a concentrations were measured by enzyme-linked im-
munosorbent assays (ELISAs). We measured concentra-
tions of the relatively small molecule C5a (11 kDa) in
the ultrafiltrate to assess whether C5a is removed from
the circulation during CVVH, and whether the anticoa-
gulation applied influences this. Commercially available
antibody duosets were used (R&D Systems, UK, Human
Complement Component C5a Duoset, DY2037). Plasma
samples and ultrafiltrate were measured in separate assays
with C5a standards prepared in a 0.5% bovine albuminserum phosphate buffered saline, 0.05% Tween solution
or fresh ultrafiltrate as appropriate. The formulas used to
assess removal of C5a from the circulation are described
in Formulas used to evaluate fluxes. Elastase and MPO
were measured by commercially available ELISAs employ-
ing a monoclonal capture antibody to polyclonal detecting
antibody with a peroxidase-detecting system. For elastase
(Hycult, The Netherlands, Human Elastase ELISA kit,
HK313) as well as for MPO (Hycult, The Netherlands,
Human MPO ELISA kit, HK324), the lower detection
limit was 0.4 ng/mL. All measurements were done accord-
ing to the protocols provided by the manufacture. Each
sample was run in duplicate and the mean concentration
was calculated. Formulas used to evaluate fluxes are de-
scribed below. Concentrations of MPO and elastase in the
ultrafiltrate were undetectable.
Formulas used to evaluate fluxes
Qi ¼ Qb  1−Htð Þ;Qo ¼ Qi
Mi ¼ Qi  Ci
Mo ¼ Qo  Co
Muf ¼ Quf  Cuf
Mtp ¼ Mo þMuf
 
−Mi
C ¼ Ci  Qi= Qi þ RFð Þ
SC ¼ 2 Cuf = C þ Coð Þ
For elastase and myeloperoxidase:
Mtp ¼ Mo−Mi
Abbreviations: Ci Concentration in inlet plasma before
addition of replacement fluid, Co Concentration in outlet
plasma, Cuf Concentration in ultrafiltrate, Qb Inlet blood
flow rate, Qi Inlet plasma flow rate, Qo Outlet plasma
flow rate, Quf Ultrafiltration flow rate, Mi Mass inlet rate,
Mo Mass outlet rate, Muf Mass ultrafiltration rate, Mtp
Mass production rate, C Concentration in inlet plasma
after addition of replacement fluid, RF Replacement fluid
flow rate, SC Sieving coefficient.
Statistical analysis
Due to the non-Gaussian distributions, data are presented
as median and range. Since there were no baseline differ-
ences between the two separate citrate groups (citrate vs.
no-anticoagulation and citrate vs. heparin, Table 1) and
there were no important differences between the groups
in courses of concentrations of C5a, elastase and MPO
over time (See Additional file 1), the citrate data were
pooled. Group differences were evaluated using the
Kruskal-Wallis or Χ2 tests. Groups were compared for
data at individual time points using the Mann–Whitney
U test. To evaluate differences according to anticoagu-
lation regimens in time we used generalized estimating
Table 1 Characteristics of patients anticoagulated with
citrate from two different studies
Observational
study (n = 10)
Randomized
study (n = 8)
P
Age, years 66 (32–79) 56 (42–74) 0.54
Sex, male 5 (50) 6 (86) 0.30
Weight, kg 75 (60–100) 80 (60–110) 0.48
Reason of admission: 0.10
Respiratory failure 5 (50) 0
Circulatory failure 1 (10) 1 (14)
Trauma 1 (10) 0
Post-resuscitation 0 2 (29)
Surgery 3 (30) 4 (57)
Sepsis 6 (60) 1 (14) 0.13
SAPS II 50 (32–60) 62 (38–86) 0.06
SOFA 13 (8–18) 14 (9–15) 0.81
Mechanical ventilation 9 (90) 7 (100) 1.00
Vasopressor dependent 8 (80) 5 (71) 1.00
Mortality in ICU 6 (60) 6 (86) 0.34
Median (range) or number (percentage) where appropriate. SAPS II: Simplified
Acute Physiology Score II; SOFA: Sequential Organ Failure Assessment score;
ICU = Intensive care unit.
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patient into account. The focus of GEE is on estimating
differences between anticoagulation groups and time
points, and their first order interaction, i.e. differences
between anticoagulation groups over time, and associatedTable 2 Patient characteristics in the anticoagulation groups
No anticoagulation n = 13
Age (years) 70 (34–84)
Sex (male) 7 (54)
Weight (kg) 70 (50–100)
Reason of admission:
Respiratory failure 2 (15)
Circulatory failure 3 (23)
Trauma 2 (15)
Post-resuscitation 2 (15)
Surgery 4 (31)
AKI 0
Sepsis 5 (39)
SAPS II 75 (43–112)
SOFA 14 (7–21)
Mechanical ventilation 12 (93)
Norepinephrine (μg/kg/min) 0.72 (0–2.8)
ICU stay (days) 5 (2–82)
Mortality in ICU 9 (69)
Median (range) or number (percentage) where appropriate. SAPS II: Simplified Acut
ICU = Intensive care unit.P values are reported. When appropriate, data were log-
transformed to achieve normal distributions (Kolmogorov-
Smirnov test P > 0.05). The values for the total mass
production rate were ranked, since some of the values were
negative and could not be log-transformed. Spearman’s
correlation coefficient was used to express relations. A
P <0.05 was considered statistically significant. Exact
P values are given unless <0.001.
Results
Patient characteristics are presented in Table 2. Thirteen
patients were treated by anticoagulant-free CVVH, 8
patients by heparin and 17 patients by citrate-CVVH. At
baseline, all patients met the criteria for SIRS and 17 pa-
tients met the criteria for sepsis. The no anticoagulation
group had a higher SAPS II score than the other groups.
Values of leukocytes, platelets, creatinine and aPTT are
presented in Table 3. The creatinine concentration at
baseline was lower in the no anticoagulation group than
in the other groups.
C5a
Prior to initiation of CVVH, C5a was detectable in all
patients at the inlet. Before initiation of CVVH, the
concentration in inlet plasma was already higher in the
citrate than in the other groups (P = 0.009) [Figure 1].
Also, the outlet concentration was higher in the citrate
group and decreased in time but less so in the citrate
group than the other groups. C5a was detectable inHeparin n = 8 Citrate n = 17 P
57 (23–81) 61 (32–79) 0.41
6 (75) 11 (65) 0.61
73.5 (55–135) 75 (60–110) 0.50
0.27
5 (63) 5 (29)
1 (13) 2 (12)
0 1 (6)
0 2 (12)
1 (13) 7 (41)
1 (13) 0
5 (63) 7 (41)
47 (37–77) 52 (32–86) <0.001
11 (8–15) 13 (8–18) 0.02
5 (63) 7 (41) 0.74
0.15 (0–1.2) 0.12 (0–1.1) 0.20
19.5 (4–48) 20 (3–81) 0.11
1 (13) 5 (29) 0.02
e Physiology Score II; SOFA: Sequential Organ Failure Assessment score;
Table 3 Laboratory data
No anticoagulation n = 13 Heparin n = 8 Citrate n = 17 P
Leukocytes (×109/L)
0 h 7.8 (1–17.2) 11.6 (6.5-19.7) 11.4 (1.3-25.7) 0.33
12 h 8.1 (1.2-24.8) 12.4 (5.2-24.2) 11.6 (0.8-116) 0.39
Platelets (×109/L)
0 h 65 (22–777) 167 (44–332) 117 (35–332) 0.03
12 h 72 (8–131) 140 (45–203) 100 (18–335) 0.04
aPTT(sec)
0 h 48 (39–72) 40 (36–81) 48 (34–94) 0.56
12 h 46 (41–118) 62 (40–125) 46 (33–68) 0.03
Creatinine (μmol/L)
0 h 249 (100–410) 420 (156–626) 311 (47–626) 0.02
24 h 206 (140–250) 284 (125–463) 236 (46–441) 0.04
Median (range). aPTT = activated partial prothrombin time.
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concentration was lowest (albeit different, Additional
file 1) in the citrate groups and decreased in time in all
groups. The sieving coefficient was low and lower in
the citrate than the other groups (no anticoagulation
0.49 (0.05-9.45), heparin 0.35 (0.12-11.2), citrate 0.10
(0.02-0.62), P < 0.001) and decreased in time in all groups
(P < 0.001). Therefore, the clearance of C5a, calculated
from ultrafiltration flow times sieving coefficient, was low
and lower in the citrate group (P = 0.001); it decreased
from 10 minutes to 720 minutes of CVVH (P < 0.001)
from 16 (2–315) ml/min to 2 (1–13) ml/min for the no
anticoagulation group, 12 (5–374) ml/min to 5 (2–11) ml/
min for heparin and from 4 (1–25) ml/min to 1 (0–2) ml/
min for the citrate group. In the heparin group, there was
C5a production across the filter which most decreased
over time as compared to other groups.
Elastase
Prior to initiation of CVVH, elastase was detectable in
all patients in inlet plasma. Over time, the concentration
at inlet increased most in the no anticoagulation as com-
pared to other groups [Figure 2]. The concentration at
outlet increased over time, mostly between 10–60 minutes,
irrespective of the anticoagulation regimens. The total
mass production was higher in the heparin group as com-
pared to the other groups and most decreased in time.
MPO
Prior to initiation of CVVH, MPO was detectable in all
patients in inlet plasma. Over time, the concentration at
inlet increased over time in all groups, but most in the no
anticoagulation group [Figure 3]. There was an increase of
MPO between 0 and 10 minutes in the heparin group.
The concentration at outlet was highest in the heparin
group as compared to the other groups; it increased overtime, particularly in the no anticoagulation group. Hence,
the total mass production was highest in the heparin
group as compared to the others groups.
Correlations
C5a directly correlated with elastase and MPO concen-
trations in inlet plasma for all groups and time points
together (elastase rs =0.37, P < 0.001; MPO rs =0.30, P <
0.001). No such correlation was found across the filter.
Sepsis and mortality
For patients with and without sepsis, there were no differ-
ences in C5a and elastase concentrations in inlet plasma
over time. For MPO however, levels of MPO were higher
in the sepsis group (166 (14–3375) ng/ml versus 84 (15–
2611) ng/ml in non-sepsis, P = 0.011). Concentrations
of C5a did not differ between outcome groups. Plasma
concentrations of elastase and MPO, however, were higher
in ICU non-survivors than in survivors (elastase: 964 (155–
7451) ng/ml versus 394 (28–4225) ng/ml, P < 0.001 and
MPO: 174 (29–2670) ng/ml versus 85 (14–1086) ng/ml,
P < 0.001).
Discussion
The present study shows that citrate, in contrast to heparin,
does not activate complement and liberate polymorpho-
nuclear neutrophil degranulation products such as elastase
and MPO when blood comes into contact with the extra-
corporeal system and the haemofilter, during CVVH in
critically ill patients with AKI. We also suggest that hep-
arin triggers endothelial release of MPO, while CVVH
with citrate does not. These findings argue in favour of cit-
rate being superior to heparin as anticoagulation in CVVH
in terms of biocompatibility.
At initiation of CVVH and throughout the study, inlet
levels of C5a were highest in the citrate group. Levels of
Figure 1 Concentration of complement product C5a measured at inlet (Ci), outlet (Co), in the ultrafiltrate (Cuf) and total mass
production rate (Mtp) over time (median and interquartile range). Results of generalized estimating equations (symbols: ● no anticoagulation
■ heparin▲ citrate) for C5a in A. Ci: highest in the citrate group (P = 0.016). B. Co: highest in the citrate group (P = 0.026), decreases over time
(P = 0.012) but least in the citrate group (P = 0.008). C. Cuf: lowest in the citrate group (P < 0.001), decreases over time (P < 0.001). D. Mtp:
decreases over time (P < 0.001), most in the heparin group (P = 0.007 for interaction).
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ministration of citrate-containing substitution fluid (at
T = 0 min), suggesting that this observation represents
a baseline difference of the citrate compared to the
other groups, rather than actual complement activation
by citrate in the patient. High inlet levels of C5a could
also explain high outlet levels in the citrate group
throughout the study. Levels of C5a in the ultrafiltrate
were lowest in the citrate group, possible partly due to
higher ultrafiltration flows and subsequent dilution, al-
though we cannot fully explain the difference between
the citrate groups, both with lower values than in theother groups. However, it is possible that the higher siev-
ing coefficient of C5a observed in the no anticoagulation
and heparin group resulted from generation of C5a in the
filter and subsequent removal in the ultrafiltrate. The
lower sieving coefficient observed when citrate was used,
may then argue in favour of less complement activation in
the filter and thus improved biocompatibility. Also, the
clearance of C5a was low and negligible in the citrate
group. This finding is in concordance with another study,
where there was hardly any C5a found in the ultrafiltrate
and thus virtually no removal by convection of C5a during
CVVH particularly when high volumes were used [17].
Figure 2 Concentration of elastase measured at inlet (Ci) and outlet (Co) and total mass production rate (Mtp) over time (median and
interquartile range). Results of generalized estimating equations (symbols: ● no anticoagulation ■ heparin▲ citrate) for elastase in A. Ci:
increases over time, most in the no anticoagulation group (P = 0.002 for interaction). B. Co: increases over time (P = 0.012). C. Mtp: highest in the
heparin group (P = 0.049), decreases over time most in the heparin group (P = 0.002 for interaction).
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citrate group with higher ultrafiltrate rates, was delayed
due to incomplete membrane saturation and adsorption
of C5a by the filter. Hence, we cannot exclude an effect of
higher ultrafiltrate rates on filter and blood contact time.
Another factor in the low clearance by convection could
be that C5a, even though a small molecule, could have
been bound to other substances, thereby exceeding size
limits for convective clearance.
Total mass production rate of C5a in the filter was
highest and thus most decreased over time in the heparin
group. Therefore, increased neutrophilic degranulation
evoked by heparin, illustrated by relatively high production
of elastase and MPO shortly after connecting the filter,
was possibly associated, at least in part, with complement
activation in the filter, in contrast to observations during
haemodialysis [18,19]. However, there was no correlation
between complement activation and neutrophil degranula-
tion across the filter whereas such correlation was present
in patient’s plasma. Moreover, there was no evidence
for neutrophil degranulation in the filter in the citrate
group and there was minimal degranulation in the no
anticoagulation group. The latter agrees with the idea
that degranulation of neutrophils is, at least partly, calcium
dependent and independent of complement activation[10,12,14,18,20]. Our finding that citrate may cause less
neutrophil degranulation by heparin during CVVH, is in
concordance with studies during intermittent haemodialy-
sis and a single study on CVVH [9,10,12,13,15]. The time
course of the release of elastase and MPO seems to be
dissimilar in our study, and release may be differently
regulated. In other studies, for instance, the use of nafa-
mostat mesylate anticoagulation during haemodialysis
completely suppressed release of MPO but did not
attenuate increases of elastase [21]. Apart from being
stored in granules in neutrophils, MPO is also widely
distributed in the endothelium of blood vessels. The
observed transient release of endothelium-bound MPO
within minutes after bolus administration of heparin to
patients agrees with the literature [16) and this pheno-
menon should be taken into account to consider plasma
MPO as an indicator of bioincompatibility [22]. Even
though the concentration of MPO in inlet plasma rose
early after start of heparin as an indicator of systemic
release, the overall concentration did not exceed that in
the other groups, thus arguing against substantial endo-
thelial release in our patients.
High serum concentrations of elastase and MPO over
time were associated with non-survival, particularly in
the no anticoagulation group, as described before in
Figure 3 Concentration of myeloperoxidase (MPO) measured at inlet (Ci) and outlet (Co) and total mass production rate (Mtp) over
time (median and interquartile range). Results of generalized estimating equations (symbols: ● no anticoagulation ■ heparin▲ citrate) for
myeloperoxidase in A. Ci: increases over time (time, P < 0.001), most in the no anticoagulation group (P < 0.001 for interaction). Note the increase
in the heparin group between T = 0 and T = 10 minutes (P = 0.024). B. Co: highest in the heparin group (P < 0.001) and increases over time
(P < 0.001), most in the no anticoagulation group (P = 0.005 for interaction). C. Mtp: highest in the heparin group (P = 0.034).
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is minimally pro-inflammatory and thus potentially
less harmful could be of value for patients. Recently
[4], it has been postulated that increased survival with
help of citrate as compared to low molecular weight
heparin-based CVVH may relate, in part, to better bio-
compatibility and our findings support this hypothesis.
Currently, citrate is often used as an alternative to heparin
in patients with a high bleeding tendency. Our results add
to the discussion whether citrate should be first choice for
regional anticoagulation during CVVH in all critically ill
patients with AKI requiring renal replacement therapy.
A limitation of the present study is that the groups were
relatively small and not completely formed by randomisa-
tion. Furthermore, the citrate group consisted of patients
from two different studies, and although patient character-
istics between groups did not differ, concentrations of
C5a in the ultrafiltrate were lower in patients from the
randomized study. This does not invalidate the conclusion
that there was less C5a in the ultrafiltrate of patients antic-
oagulated with citrate compared to the other groups.
At baseline there were differences between the anticoa-
gulation groups, by virtue of the study design. The no
anticoagulation group consisted of patients withoutsystemic anticoagulation due to a high bleeding tendency
and were indeed more severely ill, as demonstrated by
higher SAPS II and SOFA scores than in the other groups.
These baseline differences, however, may not have affected
the proof of principle in these pathophysiological studies.Conclusion
In conclusion, citrate confers less filter-induced potentially
harmful complement activation and neutrophil degranula-
tion than heparin when used for anticoagulation during
continuous venovenous haemofiltration in critically ill
patients.Additional file
Additional file 1: The concentrations of C5a, elastase and MPO in
patients anticoagulated with citrate from two studies measured at
inlet (Ci) and outlet (Co); the total mass production rate (Mtp) and,
for C5a, the concentrations in the ultrafiltrate (Cuf) and the sieving
coefficient (SC) (median and interquartile range). Results of
generalized estimating equations (symbols: ▲ observational study, n=10
▼ randomized trial, n=7): A. C5a. Cuf was lower in the randomized trial
(P<0.001). There were no differences between the citrate groups in Ci
(P=0.59), Co (P=0.74), SC (P=0.11) or Mtp (P=0.48). B. Elastase. There were
no differences between the citrate groups in Ci (P=0.56), Co (P=0.63) or
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groups in Ci (P=0.37), Co (P=0.41) or Mtp (P=0.19).
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